Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers

Shabir A. Madhi, Clare Cutland, Yuwei Zhu, Jill G. Hackell, Frances Newman, Nigel Blackburn, Brian R. Murphy, Robert B. Belshe, Ruth A Karron, Anne M. Deatly, William C. Gruber, David I. Bernstein, Peter F. Wright

Research output: Contribution to journalArticle

Abstract

Background: This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. Methods: Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a confounding infection with wtHPIV3. Following vaccination viral cultures were obtained on nine occasions to detect shedding and transmission of HPIV3cp45. Serum antibody titers were measured before and 7 weeks after vaccination. Results: No child fulfilled the criteria for transmission of HPIV3cp45 giving a risk of transmission of 0.04 (95% CI 0.01-0.19), hence establishing that HPIV3cp45 is less infectious than wtHPIV3 and risk of transmission is not a limitation to further clinical development of this vaccine candidate.

Original languageEnglish (US)
Pages (from-to)2432-2439
Number of pages8
JournalVaccine
Volume24
Issue number13
DOIs
StatePublished - Mar 20 2006

Fingerprint

Human parainfluenza virus 3
toddlers
Vaccination
pathogenicity
Vaccines
vaccination
immune response
vaccines
viruses
vaccine development
placebos
Placebos
antibodies
Antibodies
Infection
Serum
infection
methodology

Keywords

  • Immunogenicity
  • Live-attenuated
  • Parainfluenza virus type 3
  • Safety
  • Transmissibility
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. / Madhi, Shabir A.; Cutland, Clare; Zhu, Yuwei; Hackell, Jill G.; Newman, Frances; Blackburn, Nigel; Murphy, Brian R.; Belshe, Robert B.; Karron, Ruth A; Deatly, Anne M.; Gruber, William C.; Bernstein, David I.; Wright, Peter F.

In: Vaccine, Vol. 24, No. 13, 20.03.2006, p. 2432-2439.

Research output: Contribution to journalArticle

Madhi, SA, Cutland, C, Zhu, Y, Hackell, JG, Newman, F, Blackburn, N, Murphy, BR, Belshe, RB, Karron, RA, Deatly, AM, Gruber, WC, Bernstein, DI & Wright, PF 2006, 'Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers', Vaccine, vol. 24, no. 13, pp. 2432-2439. https://doi.org/10.1016/j.vaccine.2005.12.002
Madhi, Shabir A. ; Cutland, Clare ; Zhu, Yuwei ; Hackell, Jill G. ; Newman, Frances ; Blackburn, Nigel ; Murphy, Brian R. ; Belshe, Robert B. ; Karron, Ruth A ; Deatly, Anne M. ; Gruber, William C. ; Bernstein, David I. ; Wright, Peter F. / Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. In: Vaccine. 2006 ; Vol. 24, No. 13. pp. 2432-2439.
@article{57349c0d227f4d3f903405eb7a821c12,
title = "Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers",
abstract = "Background: This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. Methods: Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a confounding infection with wtHPIV3. Following vaccination viral cultures were obtained on nine occasions to detect shedding and transmission of HPIV3cp45. Serum antibody titers were measured before and 7 weeks after vaccination. Results: No child fulfilled the criteria for transmission of HPIV3cp45 giving a risk of transmission of 0.04 (95{\%} CI 0.01-0.19), hence establishing that HPIV3cp45 is less infectious than wtHPIV3 and risk of transmission is not a limitation to further clinical development of this vaccine candidate.",
keywords = "Immunogenicity, Live-attenuated, Parainfluenza virus type 3, Safety, Transmissibility, Vaccine",
author = "Madhi, {Shabir A.} and Clare Cutland and Yuwei Zhu and Hackell, {Jill G.} and Frances Newman and Nigel Blackburn and Murphy, {Brian R.} and Belshe, {Robert B.} and Karron, {Ruth A} and Deatly, {Anne M.} and Gruber, {William C.} and Bernstein, {David I.} and Wright, {Peter F.}",
year = "2006",
month = "3",
day = "20",
doi = "10.1016/j.vaccine.2005.12.002",
language = "English (US)",
volume = "24",
pages = "2432--2439",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13",

}

TY - JOUR

T1 - Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers

AU - Madhi, Shabir A.

AU - Cutland, Clare

AU - Zhu, Yuwei

AU - Hackell, Jill G.

AU - Newman, Frances

AU - Blackburn, Nigel

AU - Murphy, Brian R.

AU - Belshe, Robert B.

AU - Karron, Ruth A

AU - Deatly, Anne M.

AU - Gruber, William C.

AU - Bernstein, David I.

AU - Wright, Peter F.

PY - 2006/3/20

Y1 - 2006/3/20

N2 - Background: This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. Methods: Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a confounding infection with wtHPIV3. Following vaccination viral cultures were obtained on nine occasions to detect shedding and transmission of HPIV3cp45. Serum antibody titers were measured before and 7 weeks after vaccination. Results: No child fulfilled the criteria for transmission of HPIV3cp45 giving a risk of transmission of 0.04 (95% CI 0.01-0.19), hence establishing that HPIV3cp45 is less infectious than wtHPIV3 and risk of transmission is not a limitation to further clinical development of this vaccine candidate.

AB - Background: This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. Methods: Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a confounding infection with wtHPIV3. Following vaccination viral cultures were obtained on nine occasions to detect shedding and transmission of HPIV3cp45. Serum antibody titers were measured before and 7 weeks after vaccination. Results: No child fulfilled the criteria for transmission of HPIV3cp45 giving a risk of transmission of 0.04 (95% CI 0.01-0.19), hence establishing that HPIV3cp45 is less infectious than wtHPIV3 and risk of transmission is not a limitation to further clinical development of this vaccine candidate.

KW - Immunogenicity

KW - Live-attenuated

KW - Parainfluenza virus type 3

KW - Safety

KW - Transmissibility

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33344478717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344478717&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.12.002

DO - 10.1016/j.vaccine.2005.12.002

M3 - Article

C2 - 16406170

AN - SCOPUS:33344478717

VL - 24

SP - 2432

EP - 2439

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -